Semaphorin 6D as an independent predictor for better prognosis in clear cell renal cell carcinoma

Duan, Jiachen; Jin, Mingzhu; Qiao, Baoping

doi:10.1016/j.tranon.2022.101453

Cited by 2 publications

(2 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As in the case of breast cancer, SEMA6D seems to possess a multifaceted nature during the development of clear cell renal carcinoma (ccRCC) [59]. Although SEMA6D expression was markedly lower in ccRCC tissue samples than in normal tissue, relatively higher SEMA6D expression levels in patients with ccRCC correlated with longer diseasefree survival.…”

Section: Semaphorin 6d In Cancer Tissuesmentioning

confidence: 97%

“…The literature on cancer biology delivers numerous pieces of evidence on the role of SEMA6D in the development of various types of cancers, including osteosarcoma, CRC, lung, renal, breast, pleural mesothelioma, and gastric cancers [50,51,53,59,63,70,71,[114][115][116][117][118]. Accordingly, SEMA4D and SEMA6D have been identified as proto-oncogenes in human osteosarcoma cells, and their expression was found to be highly elevated in comparison to normal human osteoblasts [70].…”

Section: Semaphorin 6d In Cancer Tissuesmentioning

confidence: 99%

See 1 more Smart Citation

Semaphorin 6 Family—An Important Yet Overlooked Group of Signaling Proteins Involved in Cancerogenesis

Wagner,

Ochman,

Wagner

2023

Cancers

View full text Add to dashboard Cite

According to recent evidence, some groups of semaphorins (SEMAs) have been associated with cancer progression. These proteins are able to modulate the cellular signaling of particular receptor tyrosine kinases (RTKs) via the stimulation of SEMA-specific coreceptors, namely plexins (plexin-A, -B, -C, -D) and neuropilins (Np1, Np2), which share common domains with RTKs, leading to the coactivation of the latter receptors. MET, ERBB2, VEGFR2, PFGFR, and EGFR, among others, represent acknowledged targets of semaphorins that are often associated with tumor progression or poor prognosis. In particular, higher expression of SEMA6 family proteins in cancer cells and stromal cells of the cancer niche is often associated with enhanced tumor angiogenesis, metastasis, and resistance to anticancer therapy. Notably, high SEMA6 expression in malignant tumor cells such as melanoma, pleural mesothelioma, gastric cancer, lung adenocarcinoma, and glioblastoma may serve as a prognostic biomarker of tumor progression. To date, very few studies have focused on the mechanisms of transmembrane SEMA6-driven tumor progression and its underlying interplay with RTKs within the tumor microenvironment. This review presents the growing evidence in the literature on the complex and shaping role of SEMA6 family proteins in cancer responsiveness to environmental stimuli.

show abstract

Section: Semaphorin 6d In Cancer Tissuesmentioning

confidence: 97%

Section: Semaphorin 6d In Cancer Tissuesmentioning

confidence: 99%

Semaphorin 6 Family—An Important Yet Overlooked Group of Signaling Proteins Involved in Cancerogenesis

Wagner,

Ochman,

Wagner

2023

Cancers

View full text Add to dashboard Cite

show abstract

The Role of Semaphorin 6D (Sema6D) in Non-Muscle-Invasive Bladder Cancer—A Preliminary Study on Human Plasma and Urine

Purpurowicz,

Kaminski,

Kordan

et al. 2024

Biomedicines

View full text Add to dashboard Cite

The incidence of bladder cancer worldwide in the last three decades has been increasing in both men and women. So far, there is no established non-invasive bladder cancer biomarker in daily clinical practice. Semaphorin 6D (sema6D) is a transmembrane protein that belongs to the class VI semaphorins. The aim of this study was to evaluate for the first time the potential role of sema6D in bladder cancer. The study group consisted of 40 patients with non-muscle-invasive bladder cancer (NMIBC) and the control group of 20 patients without malignancies. There was a statistically significantly higher urinary sema6D concentration in patients than controls (p < 0.05) but no significant difference in plasma 6D. There were no statistically significant differences in urinary or plasma concentration of sema6D between low- or high-grade cancer and according to the tumor stage in TNM classification. There was a statistically significant negative correlation between plasma sema6D and age of patients (R = −0.6; p = 0.019). Plasma sema6D does not seem to be useful in the clinical practice at this point. However, the urinary sema6D concentration could potentially serve as a marker of NMIBC used for diagnostic purposes, monitoring, and early relapse detection or the assessment of the treatment efficacy. Urinary sema6D is probably not associated with the grading or staging of NMIBC, so it cannot be used for the prediction of disease prognosis.

show abstract

Semaphorin 6D as an independent predictor for better prognosis in clear cell renal cell carcinoma

Cited by 2 publications

References 26 publications

Semaphorin 6 Family—An Important Yet Overlooked Group of Signaling Proteins Involved in Cancerogenesis

Semaphorin 6 Family—An Important Yet Overlooked Group of Signaling Proteins Involved in Cancerogenesis

The Role of Semaphorin 6D (Sema6D) in Non-Muscle-Invasive Bladder Cancer—A Preliminary Study on Human Plasma and Urine

Contact Info

Product

Resources

About